Upstream conserved sequences of mouse leukemia viruses are important for high transgene expression in lymphoid and hematopoietic cells

Molecular Therapy

Volumn 6, Issue 3, 2002, Pages 313-320

  Wahlers, Anke ^a,b   Kustikova, Olga ^a,b   Zipfel, Peter F ^c   Itoh, Katsuhiko ^d   Koester, Markus ^e   Heberlein, Christoph ^e   Li, Zhixiong ^a,f   Schiedlmeier, Bernd ^a   Skerka, Christine ^c   Fehse, Boris ^b   Baum, Christopher ^a,f  

^a LEIBNIZ INSTITUTE FOR EXPERIMENTAL VIROLOGY   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c HANS KNÖLL INSTITUTE   (Germany)

^d KYOTO UNIVERSITY   (Japan)

^e CellTec GmbH   (Germany)

^f HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Gene therapy; Hematopoiesis; Lymphocytes; Transcription

Indexed keywords

GREEN FLUORESCENT PROTEIN; HELIX LOOP HELIX PROTEIN; RETROVIRUS VECTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NFAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING SITE; BONE MARROW CELL; CONTROLLED STUDY; EMBRYO CELL; ENHANCER REGION; ERYTHROID CELL; GEL MOBILITY SHIFT ASSAY; GENE DELETION; GENE EXPRESSION; GENE INACTIVATION; GENE SEQUENCE; GENETIC TRANSCRIPTION; HEMATOPOIETIC CELL; IN VITRO STUDY; IN VIVO STUDY; LONG TERMINAL REPEAT; LYMPHOID CELL; MOUSE; MURINE LEUKEMIA VIRUS; NONHUMAN; NUCLEOTIDE SEQUENCE; RETROVIRUS; SEQUENCE ANALYSIS; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRUS ATTENUATION; VIRUS REPLICATION;

ANIMALIA; MURINAE; MURINE LEUKEMIA VIRUS; UNIDENTIFIED RETROVIRUS;

EID: 0036764776     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1006/mthe.2002.0671     Document Type: Article

References (44)

1. Lenz, J., et al. (1984). Determination of the leukaemogenicity of a murine retrovirus by sequences within the long terminal repeat. Nature 308: 467-470.
2. Davis, B., Linney, E., and Fan, H. (1985). Suppression of leukaemia virus pathogenicity by polyoma virus enhancers. Nature 314: 550-553.
3. Stocking, C., Kollek, R. Bergholz, U., and Ostertag, W. (1986). Point mutations in the U3 region of the long terminal repeat of moloney murine leukemia virus determine disease specificity of the myeloproliferative sarcoma virus. Virology 153: 145-149.
4. Speck, N. A., et al. (1990). Mutation of the core or adjacent LVb elements of the moloney murine leukemia virus enhancer alters disease specificity. Genes Dev. 4: 233-242.
5. Baum, C., Hegewisch-Becker, S., Eckert, H.-G., Stocking, C., and Ostertag, W. (1995). Novel retroviral vectors for efficient expression of the multidrug resistance (mdr-1) gene in early hematopoietic cells. J. Virol. 69: 7541-7547.
6. Lewis, A. F., et al. (1999). Core-binding factor influences the disease specificity of moloney murine leukemia virus. J. Virol. 73: 5535-5547.
7. Halene, S., et al. (1999). Improved expression in hematopoietic and lymphoid cells in mice after transplantation of bone marrow transduced with a modified retroviral vector. Blood 94: 3349-3357.
8. Wahlers, A., Zipfel, P., Schwieger, M., Ostertag, W., and Baum, C. (2001). In vivo analysis of retroviral enhancer point mutations in hematopoietic cells: Impact of SP1/EGR1 and ETS/GATA motifs. J. Virol. 76: 303-312.
9. Golemis, E. A., Speck, N. A., and Hopkins, N. (1990). Alignment of U3 region sequences of mammalian type C viruses: identification of highly conserved motifs and implications for enhancer design. J. Virol. 64: 534-542.
10. Wang, S., et al. (1993). Cloning and characterization of subunits of the T cell receptor and murine leukemia virus enhancer core-binding factor. Mol. Cell. Biol. 13: 3324-3339.
11. Nielsen, A. L., Norby, P. L., Pedersen, F. S., and Jorgensen, P. (1996). Various modes of basic helix-loop-helix protein-mediated regulation of murine leukemia virus transcription in lymphoid cell lines. J. Virol. 70: 5893-5901.
12. Barat, C., and Rassart, E. (1998). Members of the GATA family of transcription factors bind to the U3 region of Cas-Br-E and graffi retroviruses and transactivate their expression. J. Virol. 72: 5579-5588.
13. Granger, S. W., and Fan, H. (1998). In vivo footprinting of the enhancer sequences in the upstream long terminal repeat of moloney murine leukemia virus: differential binding of nuclear factors in different cell types. J. Virol. 72: 8961-8970.
14. Zaiman, A. L., Nieves, A., and Lenz, J. (1998). CBF, Myb, and Ets binding sites are important for activity of the core I element of the murine retrovirus SL3-3 in T lymphocytes. J. Virol. 72: 3129-3137.
15. Baum, C., et al. (1997). The potent enhancer activity of the polythemic strain of spleen focus forming virus in hematopoietic cells is governed by a binding site for Sp1 in the upstream control region and by a unique enhancer motif, creating an exclusive target for PEBP/CBF. J. Virol. 71: 6323-6331.
16. Grez, M., Akgün, E., Hilberg, F., and Ostertag, W. (1990). Embryonic stem cell virus, a recombinant murine retrovirus with expression in embryonic stem cells. Proc. Natl. Acad. Sci. USA 87: 9202-9206.
17. Grez, M., Zornig, M., Nowock, J., and Ziegler, M. (1991). A single point mutation activates the Moloney murine leukemia virus long terminal repeat in embryonal stem cells. J. Virol. 65: 4691-4698.
18. Hawley, R. G., Lieu, F. H., Fong, A. Z., and Hawley, T. S. (1994). Versatile retroviral vectors for potential use in gene therapy. Gene Ther. 1: 136-138.
19. Challita, P.-M., et al. (1995). Multiple modifications in cis elements of the long terminal repeat of retroviral vectors lead to increased expression and decreased DNA methylation in embryonic carcinoma cells. J. Virol. 69: 748-755.
20. Tsukiyama, T., Ueda, H., Hirose, S., and Niwa, O. (1992). Embryonal long terminal repeat-binding protein is a murine homolog of FTZ-F1, a member of the steroid receptor superfamily. Mol. Cell. Biol. 12: 1286-1291.
21. Flanagan, J. R., Krieg, A. M., Max, E. E., and Khan, A. S. (1989). Negative control region at the 5′ end of murine leukemia virus long terminal repeat. Mol. Cell. Biol. 9: 739-746.
22. Margolis, D. M., Somasundaran, M., and Green, M. R. (1994). Human transcription factor YY1 represses human immunodeficiency virus type 1 transcription and virion production. J. Virol. 68: 905-910.
23. Romerio, F., Gabriel, M. N., and Margolis, D. M. (1997). Repression of human immunodeficiency virus type 1 through the novel cooperation of human factors YY1 and LSF. J. Virol. 71: 9375-9982.
24. Becker, K. G., Swergold, G. D., Ozato, K., and Thayer, R. E. (1993). Binding of the ubiquitous nuclear transcription factor YY1 to a cis regulatory sequence in the human LINE-1 transposable element. Hum. Mol. Genet. 2: 1697-1702.
25. Knossl, M., Lower, R., and Lower, J. (1999). Expression of the human endogenous retrovirus HTDV/HERV-K is enhanced by cellular transcription factor YY1. J. Virol. 73: 1254-1261.
26. Satyamoorthy, K., Park, K., Atchison, M. L., and Howe, C. C. (1993). The intracisternal A-particle upstream element interacts with transcription factor YY1 to activate transcription: pleiotropic effects of YY1 on distinct DNA promoter elements. Mol. Cell. Biol. 13: 6621-6628.
27. Robbins, P. B., et al. (1998). Consistent, persistent expression from modified retroviral vectors in murine hematopoietic stem cells. Proc. Natl. Acad. Sci. USA 95: 10182-10187.
28. Rao, A., Luo, C., and Hogan, P. G. (1997). Transcription factors of the NFAT family: regulation and function. Annu. Rev. Immunol. 15: 707-747.
29. Wahlers, A., et al. (2000). Influence of multiplicity of infection and protein stability on retroviral vector-mediated gene expression in hematopoietic cells. Gene Ther. 8: 477-486.
30. Decker, E. L., Skerka, C., and Zipfel, P. F. (1998). The early growth response protein (EGR1) regulates interleukin-2 transcription by synergistic interaction with the nuclear factor of activated T cells. J. Biol. Chem. 273: 26923-26930.
31. Ayuk, F., et al. (1999). Establishment of an optimised gene transfer protocol for human primary T lymphocytes according to clinical requirements. Gene Ther. 6: 1788-1792.
32. Xiao, S., et al. (1999). FasL promoter activation by IL-2 through SP1 and NFAT but not Egr-2 and Egr-3. Eur. J. Immunol. 29: 3456-3465.
33. Armesilla, A. L., et al. (1999). Vascular endothelial growth factor activates nuclear factor of activated T cells in human endothelial cells: a role for tissue factor gene expression. Mol. Cell. Biol. 19: 2032-2043
34. Lopez-Rodriguez, C., Aramburu, J., Rakeman, A. S., and Rao, A. (1999). NFAT5, a constitutively nuclear NFAT protein that does not cooperate with fos and jun. Proc. Natl. Acad. Sci. USA 96: 7214-7219.
35. Hoey, T., Sun, Y. L., Williamson, K., and Xu, X. (1995). Isolation of two new members of the NF-AT gene family and functional characterization of the NF-AT proteins. Immunity 2: 461-472.
36. Masuda, E. S., et al. (1995). NFATx, a novel member of the nuclear factor of activated T cells family that is expressed predominantly in the thymus. Mol. Cell. Biol. 15: 2697-2706.
37. Ho, I. C., Kim, J. H., Rooney, J. W., Spiegelman, B. M., and Glimcher, L. H. (1998). A potential role for the nuclear factor of activated T cells family of transcriptional regulatory proteins in adipogenesis. Proc. Natl. Acad. Sci. USA 95: 15537-15541.
38. Ranger, A. M., et al. (2000). The nuclear factor of activated T cells (NFAT) transcription factor NFATp (NFATc2) is a repressor of chondrogenesis. J. Exp. Med. 191: 9-22.
39. Cron, R. Q., et al. (2000). NFAT1 enhances HIV-1 gene expression in primary human CD4 T cells. Clin. Immunol. 94: 179-191.
40. Mouzaki, A., Doucet, A., Mavroidis, E., Muster, L., and Rungger, D. (2000). A repression-derepression mechanism regulating the transcription of human immunodeficiency virus type 1 in primary T cells. Mol. Med. 6: 377-390.
41. Hooijberg, E., Bakker, A. Q., Ruizendaal, J. J., and Spits, H. (2000). NFAT-controlled expression of GFP permits visualization and isolation of antigen-stimulated primary human T cells. Blood 96: 459-466.
42. Sweetser, M. T., et al. (1998). The roles of nuclear factor of activated T cells and ying-yang 1 in activation-induced expression of the interferon-γ promoter in T cells. J. Biol. Chem. 273: 34775-34783.
43. Doetzlhofer, A., et al. (1999). Histone deacetylase 1 can repress transcription by binding to Sp1. Mol. Cell. Biol. 19: 5504-5511.
44. Thomas, M. J., and Seto, E. (1999). Unlocking the mechanisms of transcription factor YY1: are chromatin modifying enzymes the key? Gene 236: 197-208.